Investigational Treatments for Clostridioides difficile Infection
The high recurrence rates of Clostridioides difficile infection highlight the need for novel agents with unique mechanisms of action for treating the infection.
Read More
ACX-362E a Promising Potential Treatment for C difficile, First-in-Human Phase 1 Trial Demonstrates
October 2nd 2019Investigators observed no moderate, severe, cumulative, or dose-limiting adverse events leading to discontinuation, and ACX-362E was generally well-tolerated at all dose levels.
Read More
Early Detection and Quick Infection Prevention Support Key to Tackling Candida Auris
October 2nd 2019When it came to infection prevention measures, 5 of the 9 Orange County facilities with C auris displayed hand hygiene adherence < 50%, 3 had limited access to alcohol-based hand rubs, and < 60% of assessed high-touch surfaces were clean.
Read More